Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selexipag in pulmonary arterial hypertension associated with congenital heart disease
NL-OMON43116Phase 3Withdrawn
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of selexipag in pulmonary arterial hypertension (PAH) and Cardiovascular Malformation (CVM), sponsored by Amsterdam University Medical Center. Planned start Nov 2016; status: withdrawn.
02
Drugs
selexipag
03
Conditions
pulmonary arterial hypertension (PAH)Cardiovascular Malformation (CVM)
Beyond the preview
Go deeper on NL-OMON43116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43116.